Quantcast
Last updated on April 23, 2014 at 13:36 EDT

First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian Patients With Metastatic Colorectal Cancer

March 25, 2013

Stivarga(®) (Regorafenib tablets) demonstrated extended overall survival in
patients with Metastatic Colorectal Cancer whose disease progressed
after previous treatments

TORONTO, March 25, 2013 /CNW/ – Bayer Inc. announced today the Health
Canada approval of Stivarga (regorafenib tablets), indicated for the
treatment of patients with metastatic colorectal cancer (mCRC) who have
been previously treated with fluoropyrimidine-based chemotherapy,
oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type,
an anti-EGFR therapy.(i)

“The approval of Stivarga marks the first proven option that increases
both overall and progression-free survival in patients with mCRC whose
disease has progressed after approved standard therapies,” says Dr.
Scot Dowden, medical oncologist at the Tom Baker Cancer Centre in
Calgary.  “It is a new reality for mCRC patients who are managing their
cancer and living longer – until now there was nothing to offer stage
IV patients, they had run out of options.”

The Canadian approval of Stivarga (regorafenib) is based on results from
a pivotal Phase III study (CORRECT) that demonstrated a statistically
significant improvement in overall survival (OS) and progression-free
survival (PFS) compared to placebo in patients with mCRC whose disease
had progressed after treatment with approved standard therapies. 
Stivarga (regorafenib) is an oral multi-kinase inhibitor affecting
mechanisms for tumour growth and progression – angiogenesis,
oncogenesis and the tumour microenvironment.(ii)

“New treatment options offer hope for patients living with advanced
disease and highlight the oncology community’s ongoing commitment to
patients offering not only the opportunity to improve their quality of
life, but in some cases even prolong their lives,” says Barry D. Stein,
President of the Colorectal Cancer Association of Canada. ”Stivarga
represents another new option for Canadian patients and it is important
that this innovative treatment be made accessible to all Canadians
living with metastatic colorectal cancer to ensure they have every
reasonable opportunity to combat this disease.”

“I want to make the most out of every moment,” says Stephen Dunn, stage
IV colorectal cancer patient. “Treatment options that give patients
more time are one more step on an important journey – celebrating
another day with my family means everything to me, and also to them.”

The CORRECT clinical trial achieved all of its primary and secondary
endpoints.  Pivotal Phase III data showed regorafenib plus best
supportive care (BSC) significantly improved overall survival (OS)
(HR=0.77, two-sided p-value=0.010356) and progression-free survival
(PFS) (HR=0.49, two-sided p-value<0.000001) compared to placebo plus
BSC.

Median OS was 6.4 months with regorafenib versus 5.0 months with
placebo; median PFS was 1.9 months with regorafenib versus 1.7 months
with placebo.  The data also showed a survival benefit (OS and PFS) in
the regorafenib arm across nearly all subgroups analyzed.  The most
serious adverse reactions are hepatotoxicity, hemorrhage and
gastrointestinal perforation.  The most common treatment related
adverse reactions (>=30%) are fatigue, hand-foot-skin reaction (HFSR),
diarrhea and anorexia.(iii)

“A metastatic colorectal cancer diagnosis can be overwhelming for the
patient as well as for their family and loved ones,” says Bunnie
Schwartz, Co-founder and President of Colon Cancer Canada.  “New and
available treatment options that can prolong a patient’s life are
critical – the additional time allows the patient to continue to build
memories that will be cherished by their families.”

“Stivarga’s approval in Canada further establishes Bayer as a company
committed to improving the lives of patients,” says Christian
Lauterbach, President & CEO of Bayer Inc. in Canada. “Stivarga is an
important step for Bayer in enhancing our oncology portfolio and
providing physicians and patients with new and effective tools to fight
cancer and prolong life.”

About Colorectal Cancer
Colorectal Cancer (CRC) is the third most common cancer worldwide, with
over 1.2 million cases occurring every year.(iv) It is the second leading cause of cancer death in Canada.(v ) An estimated 23,300 Canadians were diagnosed with colorectal cancer in
2012 and 9,200 died of it.(vi)

Metastatic cancer is cancer that has spread from the place where it
first started to another place in the body. A tumour formed by
metastatic cancer cells is called a metastatic tumour or a metastasis.
The process by which cancer cells spread to other parts of the body is
also called metastasis.(vii)  Of the patients with colorectal cancer, approximately 20,600 have
metastatic colorectal cancer.(viii ) mCRC is one of the most aggressive forms of cancer; however, ongoing
research and new treatment options have extended median overall
survival to more than 20 months, an increase that has changed the view
of advanced colorectal cancer from an acute to a chronic condition.(ix)

About the CORRECT Study(x)
CORRECT was an international, multicenter, randomized, double-blind,
placebo-controlled Phase III study that enrolled 760 patients with mCRC
whose disease had progressed during or within three months following
last administration of approved standard therapies. Patients were
randomized to receive regorafenib plus BSC or placebo plus BSC, as BSC
is the standard of care in this setting. Treatment cycles consisted of
160 mg of regorafenib plus BSC (or matching placebo) taken orally once
daily for three weeks on followed by one week off plus BSC.

The CORRECT study recruitment saw rapid enrollment, it opened and closed
in less than 11 months. It was unblinded in late 2011 and ended early
following a pre-planned interim analysis for efficacy.  Data determined
the regorafenib arm showed significant improvement in overall survival
achieving the primary endpoint of the study.

About Stivarga(® )(Regorafenib tablets)
Regorafenib is an oral multi-kinase inhibitor affecting mechanisms
for tumour growth and progression – angiogenesis, oncogenesis and the
tumour microenvironment. In preclinical studies, regorafenib inhibits
several angiogenic VEGF receptor tyrosine kinases that play a role in
tumour angiogenesis and lymphangiogenesis (the growth of new blood
vessels and lymphatic vessels). It also inhibits various oncogenic
and tumour microenvironment kinases including VEGFR 1-3, KIT, RET,
PDGFR, and FGFR, which individually and collectively impact upon tumour
growth, formation of a stromal microenvironment and disease
progression.

Safety and adverse events were similar to those observed with other
tyrosine kinase inhibitors (TKIS).(xi) The most frequently observed adverse drug reactions (>=30%) in patients
receiving regorafenib were asthenia/fatigue, decreased appetite and
food intake, hand-foot-skin reaction, diarrhea, mucositis, weight loss,
infection, hypertension and dysphonia. The most serious adverse drug
reactions in patients receiving regorafenib were hepatotoxicity,
hemorrhage and gastrointestinal perforation.

Regorafenib is also under investigation in metastatic and/or
unresectable gastrointestinal stromal tumours (GIST) for patients whose
disease has progressed despite prior treatment with imatinib and
sunitinib. Positive Phase III data showing a significant increase in
progression-free survival (PFS) was published in The Lancet Oncology and presented at the ASCO 2013 Meeting. Market authorization for this
indication in Canada has not yet been obtained, and the safety and
efficacy are still being reviewed for GIST, although it has been
approved for this indication in the US (February 25(th), 2013).

About Bayer Inc.
Bayer Inc. is a Canadian subsidiary of Bayer AG and the headquarters for
the Canadian operations.  Celebrating its 150 anniversary, Bayer AG is
an international research-based group with core businesses in
healthcare, crop science and innovative materials committed to creating
a better life for all through science.

In Canada, Bayer operates its healthcare business – Pharmaceuticals,
Consumer Care, Diabetes Care, Animal Health and Radiology &
Interventional – from its headquarters in Toronto, ON and its
CropScience business from Calgary, AB.

With more than 1,300 employees across the country, in 2012, Bayer had
sales of $1.6 billion CDN and invested $55.9 million CDN in research
and development in Canada. Globally, Bayer AG had sales of $39.8
billion Euro and invested $3 billion Euro in research and development.
For more information about Bayer Inc., please visit www.bayer.ca.

REFERENCES
(i) Canadian Stivarga Product Monograph, March 2013
(ii) Grothey, et al. The Lancet 21 January 2013 doi:
10.1016/S0140-6736(12)61900-X
(iii) Grothey, et al. The Lancet 21 January 2013 doi:
10.1016/S0140-6736(12)61900-X
(iv) http://www.wcrf.org/cancer_statistics/world_cancer_statistics.php
(v) http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/Stats%20at%20a%20glance/Colorectal%20cancer.aspx?sc_lang=en
(vi) http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/Stats%20at%20a%20glance/Colorectal%20cancer.aspx?sc_lang=en
(vii) http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic
(viii) SEER Data – 2008 (2005 dataset) 
(ix) The Continuum of Care: A Paradigm for the Management of Metastatic
Colorectal Cancer
Richard M. Goldberg(a), Mace L. Rothenberg(b), Eric Van Cutsem(c), Al B. Benson III(d), Charles D. Blanke(e), Robert B. Diasio(f), Axel Grothey(g), Heinz-Josef Lenz(h), Neal J. Meropol(i), Ramesh K. Ramanathan(j), Carlos H. Roberto Becerra(k), Rita Wickham(l), Delma Armstrong(m) and Carol Viele(n)
(x) Grothey, et al. The Lancet 21 January 2013 doi:
10.1016/S0140-6736(12)61900-X
(xi) Grothey, et al. The Lancet 21 Nov 2012 doi:
10.1016/S0140-6736(12)61900-X Page 8

To view a colon cancer infographic, please click here: http://files.newswire.ca/1217/ColonCancerInfoEng.pdf

SOURCE Bayer Inc.

Video with caption: “Video: First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian Patients With Metastatic Colorectal Cancer”. Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20130325_C7800_VIDEO_EN_24748.mp4&posterurl=http://photos.newswire.ca/images/20130325_C7800_PHOTO_EN_24748.jpg&clientName=Bayer%20Inc%2E&caption=Video%3A%20First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer&title=&headline=First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer

Video with caption: “Video: First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian Patients With Metastatic Colorectal Cancer”. Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20130325_C7800_VIDEO_EN_24747.mp4&posterurl=http://photos.newswire.ca/images/20130325_C7800_PHOTO_EN_24747.jpg&clientName=Bayer%20Inc%2E&caption=Video%3A%20First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer&title=&headline=First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer

Video with caption: “Video: First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian Patients With Metastatic Colorectal Cancer”. Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20130325_C7800_VIDEO_EN_24749.mp4&posterurl=http://photos.newswire.ca/images/20130325_C7800_PHOTO_EN_24749.jpg&clientName=Bayer%20Inc%2E&caption=Video%3A%20First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer&title=&headline=First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer

Video with caption: “Video: First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian Patients With Metastatic Colorectal Cancer”. Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20130325_C7800_VIDEO_EN_24746.mp4&posterurl=http://photos.newswire.ca/images/20130325_C7800_PHOTO_EN_24746.jpg&clientName=Bayer%20Inc%2E&caption=Video%3A%20First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer&title=&headline=First%20New%20Colon%20Cancer%20Treatment%20Since%202006%20Received%20Priority%20Review%20From%20Health%20Canada%20And%20Is%20Now%20Approved%20For%20Canadian%20Patients%20With%20Metastatic%20Colorectal%20Cancer

Audio with caption: “First New Colon Cancer Treatment Since 2006 Received Priority Review From Health Canada And Is Now Approved For Canadian Patients With Metastatic Colorectal Cancer”. Audio available at: http://stream1.newswire.ca/media/2013/03/25/20130325_C7800_AUDIO_EN_24753.mp3

PDF available at: http://stream1.newswire.ca/media/2013/03/25/20130325_C7800_DOC_EN_24755.pdf


Source: PR Newswire